ArticleMultiple sclerosis journal - experimental, translational and clinical
Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions.
Lisa G Schoof et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.